TAC
Brand names,
TAC
Analogs
TAC
Brand Names Mixture
TAC
Chemical_Formula
C8H8Cl3N3O4S2
TAC
RX_link
No information avaliable
TAC
fda sheet
TAC
msds (material safety sheet)
TAC
Synthesis Reference
No information avaliable
TAC
Molecular Weight
380.657 g/mol
TAC
Melting Point
No information avaliable
TAC
H2O Solubility
No information avaliable
TAC
State
Solid
TAC
LogP
1.023
TAC
Dosage Forms
No information avaliable
TAC
Indication
Used in the treatment of oedema (including that associated with heart failure) and hypertension.
TAC
Pharmacology
Trichloromethiazide is indicated as adjunctive therapy in edema associated with congestive heart failure, hepatic cirrhosis, and corticosteroid and estrogen therapy. Trichloromethiazide has also been found useful in edema due to various forms of renal dysfunction such as nephrotic syndrome, acute glomer-ulonephritis, and chronic renal failure. Trichloromethiazide is also indicated in the management of hypertension either as the sole therapeutic agent or to enhance the effectiveness of other antihypertensive drugs in the more severe forms of hypertension. Like other thiazides, Trichloromethiazide promotes water loss from the body (diuretics). They inhibit Na+/Cl- reabsorption from the distal convoluted tubules in the kidneys. Thiazides also cause loss of potassium and an increase in serum uric acid. Thiazides are often used to treat hypertension, but their hypotensive effects are not necessarily due to their diuretic activity. Thiazides have been shown to prevent hypertension-related morbidity and mortality although the mechanism is not fully understood. Thiazides cause vasodilation by activating calcium-activated potassium channels (large conductance) in vascular smooth muscles and inhibiting various carbonic anhydrases in vascular tissue.
TAC
Absorption
No information avaliable
TAC
side effects and Toxicity
Oral Rat LD50 = 5600 mg/kg, oral Mouse LD50 = 2600 mg/kg
TAC
Patient Information
No information avaliable
TAC
Organisms Affected
Humans and other mammals